A

Aclaris Therapeutics

D
ACRS
USD
0.145
(6.2771%)
Market Closed
39,579.00
Volume
-0.66
EPS
-
Div Yield
-2.993902
P/E
175,150,887.44
Market Cap
Today
8.1498%
1 Week
35.635%
1 Month
115.351%
6 Months
81.852%
12 Months
-54.747%
Year To Date
132.701%
All Time
-90.440%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ADCT
-0.255
(-8.0315%)
USD
A
AGEN
-0.385
(-8.9017%)
USD
A
ALXO
-0.003
(-0.197%)
USD
AMGN
AMGN
0.28
(0.087%)
USD
A
APPH
(%)
USD
A
ASMB
0.155
(0.9118%)
USD
A
ATNX
-0.34
(-19.6532%)
USD
B
BCRX
-0.06
(-0.7767%)
USD
B
BGNE
4.44
(2.1924%)
USD
B
BIIB
-0.32
(-0.1837%)
USD
B
BPMC
1.58
(1.5816%)
USD
C
CRSP
1.04
(2.0444%)
USD
GILD
GILD
6.23
(6.7946%)
USD
I
INCY
1.47
(1.8173%)
USD
MRK
MRK
0.46
(0.4567%)
USD
N
NBRV
0.04
(2.8369%)
USD
N
NKTR
-0.045
(-3.169%)
USD
NVS
NVS
0.23
(0.2153%)
USD
P
PTCT
-0.19
(-0.4399%)
USD
T
TBIO
(%)
USD

Title:
Aclaris Therapeutics

Sector:
Healthcare
Industry:
Diagnostics & Research
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.
Do you need help or have a question?
Contact Us